AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26725184 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg orally daily on days 2-16) plus Carboplatin (AUC=5 on day 1) and Paclitaxel (200 mg/m2 intravenously on day 1) followed by Erlotinib (150 mg orally)
Number of subjects: 59
Study 25332253 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy with chemotherapy (vincristine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide)
Number of subjects: 57
Study 25332253 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy with chemotherapy
Number of subjects: 57
Study 25332253 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 57
Study 21823052 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (training group) - 3 fast 30-min walks and 1 or 2 1-h aerobic training sessions per week
Number of subjects: 112
Study 21823052 — intervention group
Group type: COMPARATOR
Intervention: Sedentary life (controls)
Number of subjects: 112
Study 21823052 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (training group)
Number of subjects: 112
Study 21073365 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD plus CRT
Number of subjects: 1798
Study 21073365 — intervention group
Group type: COMPARATOR
Intervention: ICD alone
Number of subjects: 1798
Study 17393377 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction through reduced energy intake
Number of subjects: 64
Study 17393377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with no change in energy intake (isoenergetic)
Number of subjects: 64
Study 17393377 — intervention group
Group type: COMPARATOR
Intervention: Control group with no dietary change from habitual intake
Number of subjects: 64
Study 16301719 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 29
Study 16301719 — intervention group
Group type: COMPARATOR
Intervention: Contrast computed tomography (CT)
Number of subjects: 29
Study 12003920 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk drinking
Number of subjects: 0
Study 12003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-moderate drinking
Number of subjects: 0
Study 12003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 0
Study 12003920 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk drinkers vs. light-moderate drinkers
Number of subjects: 0
Study 12003920 — intervention group
Group type: COMPARATOR
Intervention: Non-at-risk drinkers in occupational medicine vs. primary care
Number of subjects: 0
Study 12003920 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk drinkers in occupational medicine vs. primary care
Number of subjects: 0
Study 9528868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images
Number of subjects: 42
Study 9528868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images plus post-contrast MR images
Number of subjects: 42
Study 9528868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-contrast MR images plus post-contrast plus fast dynamic MR imaging
Number of subjects: 42
Study 9528868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dynamic MR imaging
Number of subjects: 42
Study 9528868 — intervention group
Group type: COMPARATOR
Intervention: Clinical staging
Number of subjects: 42
Study 7886126 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (1000 mg twice daily)
Number of subjects: 12
Study 7886126 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (1500 mg daily, 50% higher than erythromycin estolate)
Number of subjects: 12
Study 2219563 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (lidocaine-prilocaine), applied for 60 minutes
Number of subjects: 90
Study 2219563 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (lidocaine-prilocaine), applied for over 90 minutes
Number of subjects: 90
Study 2219563 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied for 60 minutes
Number of subjects: 90
Study 2219563 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied for over 90 minutes
Number of subjects: 90
Study 77140 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine gluconate
Number of subjects: 13
Study 77140 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Number of subjects: 13
Study 77140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31289905 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFGF13A
Number of subjects: 0
Study 31289905 — intervention group
Group type: COMPARATOR
Intervention: rhFGF13B
Number of subjects: 0
Study 28521199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202
Study 28521199 — intervention group
Group type: COMPARATOR
Intervention: Diacetylmorphine
Number of subjects: 202
Study 26044714 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture needles
Number of subjects: 63
Study 26044714 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture needles
Number of subjects: 63
Study 26044714 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch sense
Number of subjects: 63
Study 26044714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision sense
Number of subjects: 63
Study 26044714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of touch and vision
Number of subjects: 63
Study 24522442 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg DHA/d (treatment)
Number of subjects: 185
Study 24522442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 185
Study 22933033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer (SP)
Number of subjects: 84
Study 22933033 — intervention group
Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 84
Study 22933033 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 84
Study 19536012 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17697170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically modified chitosan (CL)
Number of subjects: 0
Study 17697170 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified chitosan (UC)
Number of subjects: 0
Study 17697170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan adsorption
Number of subjects: 0
Study 15182773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (target 25 mg bid)
Number of subjects: 572
Study 15182773 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (target 10 mg bid)
Number of subjects: 572
Study 15182773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carvedilol and enalapril
Number of subjects: 572
Study 15182773 — intervention group
Group type: COMPARATOR
Intervention: All groups (combination, carvedilol, enalapril)
Number of subjects: 572
Study 12515648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tourniquet application throughout the operation (A group)
Number of subjects: 79
Study 12515648 — intervention group
Group type: COMPARATOR
Intervention: Control group (B group)
Number of subjects: 79
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk
Number of subjects: 85
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk
Number of subjects: 85
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk at 4 mo
Number of subjects: 85
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk at 4 mo
Number of subjects: 85
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants < or = 32 wk at 6 mo
Number of subjects: 85
Study 10591429 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infants > 32 wk at 6 mo
Number of subjects: 85
Study 10591429 — intervention group
Group type: COMPARATOR
Intervention: Term infants at 6 mo
Number of subjects: 85
Study 10591429 — intervention group
Group type: COMPARATOR
Intervention: Comparison between term infants and premature groups
Number of subjects: 85
Study 1907432 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 infusions of Na2EDTA
Number of subjects: 153
Study 1907432 — intervention group
Group type: COMPARATOR
Intervention: 20 infusions of saline
Number of subjects: 153
Study 1907432 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2EDTA
Number of subjects: 153
Study 1907432 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 153
Study 6135253 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade maintained with 100 mg metoprolol per os two hours before surgery
Number of subjects: 29
Study 6135253 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade withdrawn three days preoperatively
Number of subjects: 29
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Postabortion contraception use
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior use of contraception
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to use postabortion contraception
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of children
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation
Number of subjects: 500
Study 30471264 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion method
Number of subjects: 500
Study 28173788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-focused biofeedback
Number of subjects: 150
Study 28173788 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-focused biofeedback
Number of subjects: 150
Study 28173788 — intervention group
Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 150
Study 27122150 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (25,000 IU daily)
Number of subjects: 39
Study 27122150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23712672 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis (ORIF group)
Number of subjects: 67
Study 23712672 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing (IMN group)
Number of subjects: 67
Study 22341790 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria (Sokolow-Lyon and Cornell)
Number of subjects: 645
Study 22341790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon-1
Number of subjects: 645
Study 22341790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon-2
Number of subjects: 645
Study 22341790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell criteria
Number of subjects: 645
Study 22341790 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the 3 electrocardiographic criteria
Number of subjects: 645
Study 20515440 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA)
Number of subjects: 15
Study 20515440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18936041 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) using radiofrequency (RF) current (35W, 48 degrees C) with a 3.5 mm open irrigated tip catheter (Navistar Thermocool).
Number of subjects: 46
Study 15730048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 36
Study 15730048 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole 5 mg/kg
Number of subjects: 36
Study 12517683 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD 360 mg administered once-daily at bedtime (10 PM)
Number of subjects: 478
Study 12517683 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD 240 mg and higher administered once-daily at bedtime
Number of subjects: 478
Study 12517683 — intervention group
Group type: EXPERIMENTAL
Intervention: All GRD groups (including 540 mg and 240 mg)
Number of subjects: 478
Study 12517683 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD 540 mg administered once-daily at bedtime
Number of subjects: 478
Study 12517683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 12517683 — intervention group
Group type: COMPARATOR
Intervention: GRD 360 mg administered once-daily at 8 AM
Number of subjects: 478
Study 10379127 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 0
Study 10379127 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 0
Study 10379127 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy and curettage
Number of subjects: 0
Study 9402265 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of daily GnRHa injections for 15 days after HCG administration
Number of subjects: 38
Study 9402265 — intervention group
Group type: COMPARATOR
Intervention: Disruption of daily GnRHa injections at the day of HCG administration
Number of subjects: 38
Study 8228208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once a day)
Number of subjects: 15
Study 8228208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once a day)
Number of subjects: 15
Study 8228208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and lisinopril (once a day)
Number of subjects: 15
Study 3943269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 2 mg
Number of subjects: 6
Study 3943269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 6 mg
Number of subjects: 6
Study 3943269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 12 mg
Number of subjects: 6
Study 3943269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 24 mg
Number of subjects: 6
Study 3943269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3943269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (all doses)
Number of subjects: 6
Study 30051365 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 97
Study 30051365 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 97
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency and anemia
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine deficiency
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine excretion
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood hemoglobin level
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iron binding capacity
Number of subjects: 759
Study 26558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin saturation
Number of subjects: 759
Study 25330122 — intervention group
Group type: EXPERIMENTAL
Intervention: aprepitant + paroxetine
Number of subjects: 236
Study 25330122 — intervention group
Group type: COMPARATOR
Intervention: paroxetine + placebo
Number of subjects: 236
Study 25330122 — intervention group
Group type: EXPERIMENTAL
Intervention: aprepitant + placebo
Number of subjects: 236
Study 23190131 — intervention group
Group type: EXPERIMENTAL
Intervention: NPCT group visits
Number of subjects: 0
Study 23190131 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19786730 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (attended lecture and received booklet)
Number of subjects: 475
Study 19786730 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not attend lecture)
Number of subjects: 475
Study 19786730 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group
Number of subjects: 475
Study 19786730 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 475
Study 18828196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (PEx); median duration 12 days (range 4-28 days)
Number of subjects: 10
Study 18828196 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study 16077402 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume/low positive end-expiratory pressure (10-12 mL/kg and 2-3 cm H2O)
Number of subjects: 40
Study 16077402 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume/high positive end-expiratory pressure (8 mL/kg and 10 cm H2O)
Number of subjects: 40
Study 12123423 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin acetate
Number of subjects: 623
Study 10076936 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliding nail
Number of subjects: 80
Study 10076936 — intervention group
Group type: COMPARATOR
Intervention: Gamma nail
Number of subjects: 80
Study 8745670 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (G) 3 mg intravenously before chemotherapy
Number of subjects: 150
Study 8745670 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (O) 8 mg intravenously, followed by 8 mg orally every eight hours for the next three days
Number of subjects: 150
Study 2011253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1
Number of subjects: 106
Study 2011253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 6753090 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen administered as a single dose at night
Number of subjects: 0
Study 6753090 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen administered twice daily
Number of subjects: 0
Study 30946523 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+EBRT
Number of subjects: 263
Study 30946523 — intervention group
Group type: COMPARATOR
Intervention: ADT
Number of subjects: 263
Study 30181666 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (within 48-72 hours of admission)
Number of subjects: 151
Study 30181666 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge (after 72 hours)
Number of subjects: 151
Study 30181666 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 151
Study 30181666 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 151
Study 28754903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenoxine eye drops
Number of subjects: 0
Study 28754903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study 25681464 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 3623
Study 25681464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3623
Study 23574579 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily)
Number of subjects: 0
Study 23574579 — intervention group
Group type: COMPARATOR
Intervention: LMWH followed by warfarin (INR of 2.0-3.0)
Number of subjects: 0
Study 23574579 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0
Study 23574579 — intervention group
Group type: COMPARATOR
Intervention: LMWH followed by warfarin
Number of subjects: 0
Study 21507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus bupropion
Number of subjects: 148
Study 21507585 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 148
Study 19585106 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor) for 7-10 days
Number of subjects: 0
Study 19585106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17763613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with fractional resurfacing and ALA-PDT
Number of subjects: 4
Study 17763613 — intervention group
Group type: COMPARATOR
Intervention: Fractional resurfacing alone
Number of subjects: 4
Study 14994406 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream applied in a 10-cm strip tid for 7 days (approximately 200 mg ibuprofen per strip)
Number of subjects: 225
Study 14994406 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 225
Study 14994406 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream
Number of subjects: 225
Study 11483076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 291
Study 9481194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum amnioinfusion (AI) with 0.9% normal saline at 15 ml/min until a volume of 11 was completed, repeated if delivery did not occur within 4 hours.
Number of subjects: 60
Study 9481194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum amnioinfusion (AI)
Number of subjects: 60
Study 9481194 — intervention group
Group type: COMPARATOR
Intervention: Standard methods (control group)
Number of subjects: 60
Study 7993831 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron 1 mg bd orally for 7 days
Number of subjects: 357
Study 7993831 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron 1 mg bd orally for 7 days plus prophylactic dexamethasone (12 mg i.v.) on the first day only
Number of subjects: 357
Study 7993831 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide (3 mg/kg i.v. loading dose; 4 mg/kg i.v. infusion) plus dex (12 mg i.v.) on the first day followed by met 10 mg orally tds for a further 6 days
Number of subjects: 357
Study 2544431 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (50 mg)
Number of subjects: 6
Study 2544431 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (100 mg)
Number of subjects: 6
Study 2544431 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (200 mg)
Number of subjects: 6
Study 2544431 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (100 mg) after 15 days
Number of subjects: 6
Study 29664999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch (patch group)
Number of subjects: 142
Study 29664999 — intervention group
Group type: COMPARATOR
Intervention: No patch (control group)
Number of subjects: 142
Study 28753230 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 4675